Congress is finally taking on the middlemen driving up your drug costs

WASHINGTON EXAMINER

Every day, people walk into their local pharmacy and face a price they can’t afford for a drug they can’t live without.

Families are being forced to choose between paying for lifesaving prescriptions and covering basic necessities. At the same time, the community pharmacists who provide these critical medications are struggling to keep their doors open.

You deserve to know why this is happening and who is benefiting from it.

The answer: We are paying the price for PBM greed.

Since 2021, the House Committee on Oversight and Government Reform has investigated pharmacy benefit managers, commonly known as PBMs. PBMs operate as middlemen in the prescription drug market, negotiating with drug manufacturers, health insurers, local pharmacies, and federal health programs.

PBMs claim they lower prescription drug costs. But the evidence tells a much different story.

Our investigation, which included more than 140,000 documents and communications, exposed how PBMs use their position as middlemen to benefit themselves at the expense of patients and community pharmacists.

Read more here.